Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) shares traded up 7% during mid-day trading on Wednesday . The company traded as high as $15.47 and last traded at $15.52. 4,692 shares traded hands during trading, a decline of 36% from the average session volume of 7,378 shares. The stock had previously closed at $14.50.
Pharming Group Stock Performance
The firm's 50-day moving average price is $13.11 and its 200-day moving average price is $10.87. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.79 and a quick ratio of 2.07. The stock has a market cap of $1.05 billion, a P/E ratio of -118.04 and a beta of 0.05.
Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.16. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. The company had revenue of $93.20 million for the quarter, compared to the consensus estimate of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. Sell-side analysts expect that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Pharming Group
A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC acquired a new position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,979 shares of the company's stock, valued at approximately $32,000. Hedge funds and other institutional investors own 0.03% of the company's stock.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
